Lactobacillus salivarius UCC118 and Reduced Intestinal Inflammation

• Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.

  • 2025-02-18
  • Review
  • Theranostics 15(8)
  • • Guangze Sang
    • Bingkai Wang
    • Yujie Xie
    • Yu Chen
    • Feng Yang

  • PubMed: 40093907
  • DOI: 10.7150/thno.103983

  5 Insights on

  • Reduced Intestinal Inflammation

  • Low evidence

  Lactobacillus salivarius UCC118 has been reported to improve disease symptoms and reduce inflammation in models of intestinal disease

  Effect

  Beneficial

  Effect size

  Moderate

• Lactobacillus salivarius WZ1 Inhibits the Inflammatory Injury of Mouse Jejunum Caused by Enterotoxigenic Escherichia coli K88 by Regulating the TLR4/NF-κB/MyD88 Inflammatory Pathway and Gut Microbiota

  • 2023-03-03
  • RCT
  • Microorganisms 11(3)
  • • Zhe Wei
    • Ziqi He
    • Tongyao Wang
    • Xiaoxuan Wang
    • Tiancheng Wang
    • M. Long

  • PubMed: 36985229
  • DOI: 10.3390/microorganisms11030657

  6 Insights on

  • Reduced Intestinal Inflammation

  • Low evidence
  • Animal Study
  • Clinical

  pretreatment with Lactobacillus salivarius WZ1 can dramatically protect the jejunum morphological structure from the changes caused by ETEC K88 and relieve the morphological lesions of the jejunum, inhibiting changes in the mRNA expressions of TNF-α, IL-1β and IL-6

  Effect

  Beneficial

  Effect size

  Moderate